Investors looking for an edge in the market have flocked to our free Profit Alerts service, where we provide Money Morning readers with the top marijuana stocks to watch each week.
And for readers who already signed up for Profit Alerts (you can sign up here), we sent an alert on April 4 about the first marijuana ETF trading anywhere in the world.
The Horizons Medical Marijuana Life Sciences ETF debuted on the Toronto Stock Exchange (TSE) on April 5 under the symbol HMMJ. And when reviewing HMMJ's performance thus far, I found a new profit opportunity.
One stock in HMMJ's holdings is expected to climb 27% over the next 12 months.
And that's just a conservative estimate.
In fact, one projection shows the stock price climbing 66% in the next year.
Now, I know what you're thinking: Most pot stocks are penny stocks right now and trade on over-the-counter (OTC) markets.
And you're correct. There are certainly risks to investing in marijuana stocks, but there is also a tremendous profit opportunity...
The Risks of Owning Marijuana Stocks
Penny stocks are known for volatile price swings, and OTC markets aren't regulated the same as major indices like the New York Stock Exchange (NYSE) and Nasdaq. And because marijuana is illegal under federal law right now, all of these reasons make investing in cannabis stocks speculative.
However, HMMJ only invests in public companies that are in legal and regulated segments of the marijuana industry. That's part of what makes the marijuana stock we're watching today so intriguing.
The Marijuana Gold Rush
According to its website, "HMMJ will initially not include exposure to companies involved in the medical marijuana industry in jurisdictions like the United States where it is still illegal under federal law."
This marijuana stock also trades on the Nasdaq. That means it's regulated like any other stock that trades on this major index, while still offering massive upside.
It's already climbed 59.08% in 2017, and that's just the beginning of the profit potential this stock could offer...
One of the Top Marijuana Stocks to Watch in 2017
[mmpazkzone name="end-story-hostage" network="9794" site="307044" id="138536" type="4"]
The third-largest holding in the Horizons Medical Marijuana Life Sciences ETF is Zynerba Pharmaceuticals Inc. (Nasdaq: ZYNE).
Zynerba is a clinical-stage pharmaceutical company that develops innovative transdermal synthetic cannabinoid treatments for patients with unmet medical needs.
"Our mission is to improve the lives of patients battling severe health conditions including epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain through these therapeutics," ZYNE said on its website.
Currently, the company is developing a product with a cannabidiol (CBD) gel called ZYN002. It's the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
It's currently in phase 2 clinical development to help patients with refractory epilepsy, osteoarthritis of the knee, and patients with Fragile X syndrome (a genetic condition causing intellectual disability).
The company also has a product in its pipeline called ZYN001. It's being developed to help patients with fibromyalgia and peripheral neuropathic pain. The drug enables transdermal delivery through the skin and into the circulatory system through a patch.
According to the company's website, the phase 1 study for ZYN001 is expected to happen in the first half of 2017.
Because of these two revolutionary drugs, analysts are bullish on ZYNE stock. According to FactSet, the average one-year price target from firms covering ZYNE is $32. From today's opening price of $25.17, that's a potential profit of 27.13%.
And as we mentioned earlier, that may be too conservative...
On April 10, investment bank Piper Jaffray set a one-year price target of $42 for ZYNE stock. That means in the next 12 months, ZYNE could climb over 66%.
While we're focusing this week on ZYNE, our readers know there are a lot of other ways to play the booming cannabis industry...
The vote across America for marijuana legalization is expected to create one of the biggest wealth grabs in history, transforming everyday Americans into millionaires overnight.
That's why Money Morning Director of Technology & Venture Capital Research Michael A. Robinson has created the "bible of weed investing" for Money Morning readers.
Who Is Marijuana Stock Guru Michael Robinson?
Michael is one of our most prominent and respected investing "gurus" here at Money Map Press - and for good reason. He is one of the top financial analysts working today. Make no mistake: Michael's ideas are completely his own. He's a true original. He works solely for Money Map Press... and receives absolutely no compensation from companies he writes about.
His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style.
Michael's 30-year track record as a leading tech analyst has garnered him rave reviews, too.
As editor of the financial newsletter American Wealth Underground, Michael amassed an amazing track record using rigorous investing. The first analyst to uncover the rare earth mineral crisis, he amassed cumulative gains of 990% for his readers in just 16 months.
His research is world class, too. The Oakland Tribune, Detroit News, The San Francisco Examiner, The Kansas City Times, Wealth Magazine, and American Banker all publish his reporting. He has appeared on Larry King's syndicated radio show.
Robinson has an honors economics degree from the University of Missouri at Columbia with a minor in journalism.
And as a service to Money Morning readers, we're now making available a 90-page cannabis investing guide called The Roadmap to Marijuana Millions.
This "bible of weed investing" reveals the world's top marijuana stocks every serious investor should consider right now.
Normally valued at $499, it can be yours absolutely free. To learn how to get your free copy, click here.
This offer is only available to the first 500 people who respond today. So please go here now to reserve your copy.